BACKGROUND: Over the last decade, the causal link between human papillomavirus (HPV) infection and squamous cell carcinoma of the anus (SCCA) has been well described. Because HPV infection in one site is often associated with other sites of infection, it then follows that patients with SCCA may have an increased risk of additional HPV-related cancers. Identifying and targeting at-risk sites through cancer screening and surveillance may help to guide best practices. The current study sought to ascertain sites and risk of HPV-related second primary malignancies (SPMs) in survivors of SCCA. METHODS: Using population-based data from 1992 through 2012, the authors identified patients with SCCA and determined their risk of HPV-related SPMs, including anal, oral, and genital cancers. Standardized incidence ratios (SIRs), defined as observed to expected cases, were calculated to determine excess risk. RESULTS: Of 10,537 patients with SCCA, 416 developed HPV-related SPMs, which corresponded to an overall SIR of 21.5 (99% confidence interval [99% CI], 19.0-24.2). Men were found to have a higher SIR (35.8; 99% CI, 30.7-41.6) compared with women (12.8; 99% CI, 10.4-15.5). SIRs for a second SCCA were markedly higher in men (127.5; 99% CI, 108.1-149.2) compared with women (47.0; 99% CI, 34.7-62.1), whereas SIRs for oral cavity and pharyngeal cancers were elevated in men (3.1; 99% CI, 1.5-5.7) and women (4.4; 99% CI, 1.5-9.7). SIRs for sex-specific sites also were elevated, with male genital cancers having an SIR of 19.6 (99% CI,) and female genital cancers an SIR of 8.3 (99% CI, 6.1-11.0). CONCLUSIONS: Patients with index SCCA are at an increased risk of subsequent HPVrelated SPMs. The elevated risk is most striking in patients with second primary SCCAs; however, the risk of second cancers also appears to be increased in other HPV-related sites. Cancer 2017;123:4013-21.
INTRODUCTION
Second primary malignancies (SPMs) account for 17% to 19% of new cancer cases. 1, 2 The risk of SPM in patients with cancer is multifactorial, but is related to genetic predispositions, treatment-related malignant transformations, and/or continuing exposure to the etiologic agents. 3 By 2026, there will be >20 million cancer survivors in the United States at risk of SPMs. 4 Over the last decade, the human papillomavirus (HPV) has been identified, associated with, and found to be the main etiologic agent in cancers of the oropharynx and anogenital regions of men and women. [5] [6] [7] [8] In addition, coinfection with other viruses, such as the human immunodeficiency virus, increases the risk of HPV-related malignancies. [9] [10] [11] The rising incidence of these cancers in parallel with the high prevalence of HPV infection has been widely reported and attributed to factors such as changing sexual practices 12 and cross-infection at multiple anatomic sites. 13, 14 With the risk of cancer resulting from HPV infection, the lifestyle factors associated with this infection, and the correlation of HPV infection at one site with HPV infection at other sites, patients diagnosed with one HPV-related cancer may be at an increased risk of developing HPV-related SPMs. Recent studies have suggested an elevated risk of HPVrelated SPMs in survivors of HPV-related cancers. Women with a history of cervical cancer were found to be at a greater risk of developing HPV-related SPMs at other sites, such as anogenital and oropharyngeal malignancies. [15] [16] [17] The increased risk of SPM in other head and neck sites also has been found in patients with HPV-related oropharyngeal cancers. 18, 19 The goals of the current study were to better define and quantify risk, to identify anatomic sites most at risk, and to better understand the demographic and treatment characteristics of patients at highest risk of an HPV-related SPM after an index squamous cell cancer of the anal canal (SCCA). The findings of the current study may provide potential insight into cancer screening and surveillance for survivors of anal cancer.
MATERIALS AND METHODS
We conducted a cohort study examining the risk of SPMs in patients after the diagnosis of SCCA. Patients diagnosed from 1992 through 2012 were identified using the Surveillance, Epidemiology, and End Results (SEER) data set for the SEER 13 registries. SEER 13 20 represents approximately 13.4% of the US population and includes San Francisco-Oakland, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle/Puget Sound, Utah, Atlanta, San Jose-Monterey, Los Angeles, and Rural Georgia.
Index Case Characteristics
The study cohort included patients diagnosed with in situ or invasive cancer of the anus, anal canal, or anorectum (International Classification of Diseases for Oncology, 3rd Edition [ICD-O-3] codes C210-C212 and C218, excluding ICD-O-3 histologies 9050-9055, 9140, and 9590-9992) who presented with their first cancer between 1992 and 2012. Similar to the study by Morris et al, 21 patients were included only if they had a 6-month event-free latency period, which allowed for a conservative definition of metachronous cancers. We limited our results to include only squamous cell histologies (ICD-O-3 codes 8000-8131 and 8980-8981) and excluded patients diagnosed based on autopsy or death record information. Last, we included only patients for whom the index SCCA was their first malignancy. Figure 1 shows the complete stepwise selection criteria. The final sample included 10,537 patients with an index SCCA. Of these, 416 patients were identified as having an HPV-related SPM. An additional 757 patients with non-HPV-related SPMs, such as cancers of the lung, breast, or bladder, were excluded from all analyses.
HPV-Related SPMs
Standardized incidence ratios (SIRs) and absolute excess cases for cancers of the oral cavity/pharynx, anal canal, female genital organs, and male genital organs were calculated for the patients with HPV-related SPMs. The complete breakdown of HPV-related SPMs by cancer subtype is listed in Supporting Information Table S1 . Of the 416 patients, 375 (90%) had 1 additional HPV-related SPM, whereas 41 patients (10%) had 2 additional HPVrelated SPMs. We included all 463 malignancies in the final SIR estimates.
Statistical Analysis
Demographic characteristics of the 416 patients were compared with the 10,121 patients who did not develop an SPM. Categorical data were compared using chisquare tests for nominal data and Jonckheere-Terpstra nonparametric tests for ordinal data. Univariate and multivariate logistic regression models were used to identify factors associated with HPV-related SPMs. Results were reported using odds ratios (ORs) and 95% confidence intervals (95% CIs).
SIRs for HPV-related SPMs, defined as the ratio of the observed over expected (O/E) number of cases, were calculated and adjusted by person-years at risk. The expected number of cases was based on population-based incidence rates calculated by SEER and group stratified to HPV-related SPM cases by age, sex, race, and year of index diagnosis (available at http://seer.cancer.gov). The CIs were calculated using the exact method and were considered statistically significant if the 99% CI did not include 1.0. 22 Absolute excess risk, defined as the difference in the number of O/E cases per 10,000 person-years, also was reported. As noted by Morris et al, excess risk estimates correspond to approximately 1 excess case per 1000 patients followed for 1 decade. 23 Additional stratification based on sex, age, stage of disease, and latency since diagnosis of the index case were included in the current analyses. The latency variable is available in the SEER*-STAT application and can be grouped according to time intervals of interest. For the current study, we grouped latency (time since the initial diagnosis to the second primary diagnosis) into the following: 0.5 to 1 year, >1 to 5 years, >5 to 10 years, >10 to 15 years, and >15 years. For sex-specific sites, the SIRs and excess risk statistics apply only to the relevant sex. All analyses were performed using SAS statistical software (SAS Institute Inc, Cary, NC) and SEER*Stat software (version 8.2.1, 04.07.15 build; http://seer.cancer.gov/seerstat/software). SEER public use 1992 through 2012 research data were obtained from the SEER Web site (http://seer.cancer.gov/ data/). These data first were released in April 2015 and were based on the November 2014 data submission. Multiple primary SIRs were developed by SEER in collaboration with the Radiation Epidemiology Branch of the Division of Cancer Epidemiology and Genetics at the National Cancer Institute.
RESULTS

Demographics of Patients With HPV-Related SPMs
Of the 10,537 patients with an index SCCA, 416 patients developed HPV-related SPMs ( Table 1 Table S2 . SEER categorizes oropharyngeal sites within the oral cavity and pharynx group.
As shown in Table 2 , younger patients (defined as those aged below the median of 49 years) had a higher overall SIR of 43.6 (99% CI, 36.7-51.4) compared with 13.9 (99% CI, 11.6-16.5) in older patients. The sites with the highest SIRs for HPV-related SPMs in the younger age group were the anus and anal canal (SIR, 127. (Table 3) .
After stratifying latency times between index cancers and SPMs (0.5-1 years, >1-5 years, >5-10 years, >10-15 years, and >15 years), the highest SIRs occurred during the first 5 years after the index cancer diagnosis for both men and women. Specifically, the highest SIRs occurred from >1 to 5 years after the index diagnosis (SIRs of 46.2 and 16.8, respectively, for men and women) (Fig. 3) . Although the SIRs for men and women were lower in the time period after 5 years when compared with the time period from 1.1 to 5 years, the SIR for an HPV-related SPM remained elevated even 15 years after the index SCCA diagnosis. Original Article risks were highest for cancers of the anus and anal canal in both men and women; however, the combined excess risk in female genital cancers was comparable to the excess risk of anus and anal canal cancers in women. Oral cavity and pharyngeal cancers had the lowest excess risk in both sexes, with an average of 3 extra cases per 10,000 person-years. The excess risk of male genital cancers was similar at 4 per 10,000 person-years.
Primary SCCA Characteristics by Sex
Stratification by sex demonstrated significant demographic and clinical differences between men and women who developed SPMs. The age at the time of the initial presentation of the index SCCA was younger in men, with a median age of 46 years (range, 39-53 years) whereas women presented at a median age of 53 years (range, 45-67 years) (P<.0001) ( Table 4) . Men more frequently presented with in situ index disease compared with women (77.2% vs 47.3%; P<.0001) ( Table 4) , and men were less likely to undergo radiotherapy (14.9%) than women (39.2%) (P<.0001).
DISCUSSION
Over the last decade, the dramatic increase in the prevalence of HPV infections parallels increases in rates of HPV-related cancers such as SCCA. 24 Studies also have shown that patients who are infected with HPV in one anatomic site are at risk of infection in other HPV-related sites.
14 Whether survivors of HPV-related index cancers are at risk of HPV-related SPMs remains to be fully elucidated. A recent study from France demonstrated that the overall risk of a second HPV-related cancer was elevated (SIR, 2.48; excess absolute risk, 130.5), but only in men with an index HPV-related head and neck cancer. However, an increased risk of HPV-related SPM was not shown in men with index primary tumors in other HPVrelated sites. 17 In addition, studies from the United States have shown both a decreased risk of head and neck SPMs in patients with a history of oropharyngeal cancers 23, 25 as well as an elevated risk of SPMs in other HPV-related sites. 21 The evidence for women with a history of HPVrelated cervical cancer with elevated SIRs of other HPVrelated cancers has been more consistent. Balamurgan et al reported this excess risk in the US whereas several other groups reported similar results in other countries. 15, 18, 26, 27 In addition, the results of a prospective study confirmed that women with a history of HPVrelated lower genital tract dysplasia and malignancy have higher rates of anal dysplasia and anal cancer. 28 A recent study found an increased risk of SPMs in patients with SCCA. This study included patients with an index invasive SCCA only and examined all second cancers regardless of their relationship to HPV. 29 In contrast, the current study included patients with index in situ, local, regional, and distant stage SCCA to ensure that we studied the impact of SPMs in patients with all stages of index cancer. In particular, the population with index in situ disease was found to have the longest survival rates, resulting in more years at risk of SPMs. The current study also sought to further delineate the risk of an SPM as a potential consequence of a common viral exposure and therefore our analyses were focused on HPV-related SPMs only.
The current study analyses found that patients with an index SCCA have a markedly increased risk of SPMs in HPV-related sites. Men had a higher SIR than women (35.8 vs 12.8). In men, site-specific SIRs were found to be elevated in cancers of the anus and anal canal (128.0), oral cavity and pharynx (4.0), and male genital organs (19.6) . In women, site-specific SIRs were elevated in cancers of the anus and anal canal (47.0), oral cavity and pharynx (4.4), and female genital organs (8.3) . It is interesting to note that cervical SPMs demonstrated little elevation; however, SEER mandatory reporting rules for cervical intraepithelial neoplasia 3 and in situ cervical cancer changed for cases diagnosed after January 1, 1996 when case collection was no longer required, resulting in a lack of data regarding early cervical SPMs in women with an index SCCA (https://seer.cancer.gov/registrars/data-collection.html). In addition, because the median age at the time of SCCA diagnosis is later than that of cervical cancer (62 years vs 48 years; SEER data, not shown), women diagnosed with both malignancies were likely diagnosed with cervical cancer first. The difference in age at the time of presentation is supported by a French study of women in which the mean age at the time of diagnoses was found to be 54 years for cervical cancer versus 68 years for anal cancer. 17 The difference in age at the time of the index diagnosis may have excluded some women with cervical cancer from the current study.
To quantify the number of extra HPV-related cancer cases that resulted from the elevated SIRs, we calculated absolute excess risk statistics. Overall, for every 10,000 person-years, there were 88 extra cancer cases in men and 54 extra cancer cases in women at HPV-related sites. Although these excess cases were predominately SPMs found in the anus and anal canal, cases also occurred in the oral cavity and pharyngeal sites as well as sex-specific genital sites such as the vulva and vagina in women and the penis in men. These findings are consistent with the hypothesis that HPV exposure markedly increases the risk of SPM across all HPV-related sites.
Using univariate and multivariate logistic models, we examined demographic and clinical factors associated with HPV-related SPMs after diagnosis of an index SCCA. We found that patients with SPMs were more often young and male, and presented with early-stage index disease. These findings are consistent with our current understanding of SCCA. Patients who are younger at the time of index diagnosis have more years of risk associated with ongoing exposure to HPV. 17 The same is true of patients with index disease of an earlier stage, because the competing risk of dying of their index cancer is lower. Although the risk of HPV-related SPM is highest at 1 to 5 years after the index diagnosis, increases in risk remain 15 years after diagnosis. This was particularly true for men. The SIR was 21.7 times higher than expected after 15 years since diagnosis of the index SCCA. By comparison, women were found to have an SIR of 2.3 after 15 years.
Conclusions
Patients with a history of anal cancer have higher rates of HPV-related SPMs. This risk is significant in men and women across all HPV-related sites. Because SCCA often presents early and treatment is effective, the extended survival rates likely impact the development of SPMs. Further studies are needed to determine the benefits of systematic screening and surveillance programs for patients with an index anal cancer.
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